Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGC Canopy Growth	$1.24 -3.9%	$1.42	$0.77 ▼ $8.65	$237.19M	0.75	6.12 million shs	6.13 million shs
DBVT DBV Technologies	$9.40 -4.6%	$9.14	$2.20 ▼ $12.78	$269.79M	-0.63	190,367 shs	22,359 shs
IMMX Immix Biopharma	$2.24 -6.3%	$2.08	$1.26 ▼ $3.00	$66.63M	0.31	155,648 shs	139,384 shs
TSVT 2seventy bio	$5.00	$4.99	$2.29 ▼ $5.30	$266.15M	1.04	643,449 shs	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGC Canopy Growth	-3.88%	-16.22%	-31.11%	+11.71%	-82.51%
DBVT DBV Technologies	-4.57%	+3.30%	+0.75%	+88.38%	+92.11%
IMMX Immix Biopharma	-6.28%	-4.68%	+7.18%	+24.44%	+11.44%
TSVT 2seventy bio	0.00%	0.00%	0.00%	+1.01%	+28.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGC Canopy Growth	2.2196 of 5 stars	2.5	2.0	0.0	0.0	1.9	0.0	1.3
DBVT DBV Technologies	3.3865 of 5 stars	3.3	5.0	0.0	0.0	3.0	2.5	0.6
IMMX Immix Biopharma	2.6963 of 5 stars	3.5	3.0	0.0	0.0	2.5	1.7	0.6
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGC Canopy Growth	1.00	Sell	$2.00	61.29% Upside
DBVT DBV Technologies	2.50	Moderate Buy	$14.75	56.91% Upside
IMMX Immix Biopharma	3.00	Buy	$7.00	212.50% Upside
TSVT 2seventy bio	2.00	Hold	$5.00	N/A

Current Analyst Ratings Breakdown

Latest IMMX, CGC, TSVT, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/10/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/24/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/8/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
3/22/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGC Canopy Growth	$225.65M	1.01	N/A	N/A	$1.90 per share	0.65
DBVT DBV Technologies	$4.15M	62.04	N/A	N/A	$1.42 per share	6.62
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
TSVT 2seventy bio	$48.37M	5.50	N/A	N/A	$5.04 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGC Canopy Growth	-$429.86M	-$4.04	N/A	N/A	N/A	-195.76%	-88.54%	-40.78%	8/8/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
IMMX Immix Biopharma	-$21.61M	-$0.70	N/A	N/A	N/A	N/A	-130.02%	-86.33%	8/11/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$0.10	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	8/6/2025 (Estimated)

Latest IMMX, CGC, TSVT, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	$45.30 million
5/7/2025	Q1 2025	TSVT 2seventy bio	-$0.10	$0.01	+$0.11	$0.01	$13.96 million	$22.94 million
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million
3/25/2025	Q4 2024	TSVT 2seventy bio	-$0.23	-$0.31	-$0.08	-$0.37	$12.84 million	$2.93 million
3/24/2025	Q4 2024	IMMX Immix Biopharma	-$0.25	-$0.16	+$0.09	-$0.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGC Canopy Growth	0.62	3.12	2.10
DBVT DBV Technologies	N/A	0.72	0.72
IMMX Immix Biopharma	N/A	1.80	1.80
TSVT 2seventy bio	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGC Canopy Growth	3.33%
DBVT DBV Technologies	71.74%
IMMX Immix Biopharma	11.26%
TSVT 2seventy bio	93.90%

Insider Ownership

Company	Insider Ownership
CGC Canopy Growth	1.30%
DBVT DBV Technologies	1.44%
IMMX Immix Biopharma	55.40%
TSVT 2seventy bio	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGC Canopy Growth	3,150	183.87 million	181.48 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
IMMX Immix Biopharma	9	27.88 million	12.43 million	Optionable
TSVT 2seventy bio	440	53.23 million	47.87 million	Optionable

IMMX, CGC, TSVT, and DBVT Headlines

Recent News About These Companies

2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Western Standard LLC

May 22, 2025 | marketbeat.com

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

May 7, 2025 | businesswire.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

April 16, 2025 | businesswire.com

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

March 27, 2025 | markets.businessinsider.com

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

March 25, 2025 | businesswire.com

Jessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

March 20, 2025 | insidertrades.com

2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why

March 17, 2025 | zacks.com

2seventy Bio price target lowered to $5 from $6 at Morgan Stanley

March 14, 2025 | markets.businessinsider.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

March 14, 2025 | businesswire.com

2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in Stock

March 14, 2025 | insidertrades.com

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

March 13, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT

March 12, 2025 | prnewswire.com

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders

March 11, 2025 | businesswire.com

2seventy bio accepts Bristol Myers’ takeover bid

March 11, 2025 | thepharmaletter.com

Biotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition News

March 11, 2025 | investorideas.com

TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders

March 11, 2025 | tmcnet.com

2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash

March 11, 2025 | markets.businessinsider.com

TSVT Up on Acquisition Agreement With BMY for $286 Million

March 11, 2025 | zacks.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

March 11, 2025 | prnewswire.com

Bristol Myers buys out cell therapy partner 2seventy bio

March 11, 2025 | endpts.com

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

March 10, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, CGC, TSVT, and DBVT Company Descriptions

Canopy Growth NASDAQ:CGC

$1.24 -0.05 (-3.88%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.27 +0.03 (+2.82%)

As of 06/20/2025 07:59 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

DBV Technologies NASDAQ:DBVT

$9.40 -0.45 (-4.57%)

Closing price 06/20/2025 03:46 PM Eastern

Extended Trading

$9.59 +0.19 (+2.02%)

As of 06/20/2025 04:48 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Immix Biopharma NASDAQ:IMMX

$2.24 -0.15 (-6.28%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.22 -0.02 (-0.89%)

As of 06/20/2025 05:01 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

2seventy bio NASDAQ:TSVT

$5.00 0.00 (0.00%)

As of 05/13/2025

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time